BioNexus Gene Lab Corp. (BGLC) vs Rio Tinto Group (RIO.AX)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BGLC | RIO.AX | |
|---|---|---|
| Sector | Basic Materials | Basic Materials |
| Industry | Specialty Chemicals | Other Industrial Metals & Mining |
| Size band | NANO | LARGE |
| Listing | Nasdaq CM | ASX |
| Country | Malaysia | United Kingdom |
| Theme | diagnostics | iron-ore |
| Price and returns | ||
| Last close | $1.16 | 146.61 AUD |
| Return · 1 week | −5.54% | −5.32% |
| Return · 1 month | −10.77% | −10.08% |
| Return · 3 months | −14.07% | −11.35% |
| Return · year to date | −70.56% | +1.56% |
| Return · 1 year | −77.08% | +12.36% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −80.30% | −25.14% |
| 52-week high | $5.89 | 195.84 AUD |
| 52-week low | $1.07 | 125.50 AUD |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $3.40M | $167.37B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $7.66K | $147.82M |
| Employees | 19 | 56,890 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 13.99× |
| Price to earnings · forward | — | 12.79× |
| Price to sales | 1.12× | 3.96× |
| Price to book | 0.37× | 2.62× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 11.68× |
| Enterprise value to revenue | 0.09× | 4.33× |
| PEG ratio | — | 14.02 |
| Earnings per share · trailing | -1.25 | 10.74 |
| Profitability | ||
| Gross margin | 12.34% | — |
| Operating margin | −398.69% | 28.05% |
| Profit margin | −82.36% | 19.58% |
| Return on equity | −33.66% | 19.31% |
| Return on assets | −18.99% | 8.11% |
| Growth | ||
| Revenue growth | −96.60% | +15.50% |
| Earnings growth | — | +46.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | 4.16 | 31.87 |
| Current ratio | 6.08 | 1.42 |
| Dividend yield | 0.00% | 4.35% |
| Payout ratio | 0.00% | 53.44% |
| Trend and volatility | ||
| RSI · 14 | 37.38 | 27.34 |
| ADX · 14 | 7.82 | 30.61 |
| 50-day average | $1.39 | 166.91 AUD |
| 200-day average | $2.02 | 167.87 AUD |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 5.89% | 2.61% |
The full BGLC analysis
Everything this table leaves out for BioNexus Gene Lab Corp.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BGLC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BGLC analysisThe full RIO.AX analysis
Everything this table leaves out for Rio Tinto Group: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the RIO.AX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full RIO.AX analysis